Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Solid State Boost at Onyx

Published: Tuesday, December 10, 2013
Last Updated: Tuesday, December 10, 2013
Bookmark and Share
Company unveils huge increase in demand for solid-state chemistry services.

Onyx Scientific has unveiled a huge increase in demand for its solid-state chemistry services versus last year.

The contract research and manufacturing organization has reported a 45% uplift in solid formulation related revenues, which is being driven by early stage drug development projects.

The company’s close alliance with Molecular Profiles, announced last year, has also led to more work as a result of increasing activity in the biotechnology and early stage clinical sector.

Denise Bowser, commercial director at Onyx Scientific, said: “Over the past few years, we have proudly become a real specialist in solid-state chemistry focused on providing detailed investigation to cut lead times for clients and ensure processes are scalable.

“As many drugs are formulated in solid dosage form, the need to understand, control and characterize the individual forms of a substance, in particular the polymorphic form, is vital. This is why we feel we have seen such an increased demand.”

In 2013, the company has worked with pharmaceutical and biotech clients across the globe assisting with integrated chemistry, process development and custom synthesis projects.

With MHRA and FDA facilities in the UK and India, Onyx Scientific assists companies from medicinal chemistry and preclinical through Phase I-III, scaling-up to large scale commercial API production.

Its UK-based labs deal with complex chemistry to deliver early stage programs and is then able to scale-up, tech transfer and increase project efficiency using its commercial manufacturing sites in India.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

CRO to Expand GMP Capability
Company will install a new Class 100,000 suite at its facility in North East England.
Thursday, April 02, 2015
Onyx to Expand Capabilities
Reach alliance broadens specialist purification, separation services.
Tuesday, August 07, 2012
Onyx Strengthens Commercial Team
Appointment of Brian Jolly as director of European business development.
Monday, May 28, 2012
API Firm Posts Impressive Growth
UK-based Onyx Scientific has grown 27% as the business continues to build its pharmaceutical and biotech client-based in Europe, Japan and the US.
Thursday, June 02, 2011
Onyx Scientific Clinches Cancer Research UK Contract
Cancer Research UK has selected Onyx Scientific to develop the chemistry and perform the GMP synthesis of the API for use in a Phase 1 clinical trial.
Thursday, May 12, 2011
Scientific News
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Scientists Test New Gene Therapy for Vision Loss from a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Multi-Gene Test Enables Some Breast Cancer Patients to Safely Avoid Chemotherapy
A major study is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid chemotherapy.
Low Dose Beta-Blockers As Effective As High Dose After a Heart Attack?
Heart attack patients live as long – or even longer – on one-quarter the suggested dose.
Antidepressants Plus Blood-Thinners Slow Down Brain Cancer
EPFL scientists have found that combining antidepressants with anticoagulants slows down brain tumors (gliomas) in mice.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Electronic Reminders Keep TB Patients on Track With Medication In China
Giving electronic reminders to tuberculosis (TB) patients in China can reduce the amount of medication doses they miss by half, according to new research.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos